GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anti-Microbial Savior BioteQ Co Ltd (ROCO:6864) » Definitions » Equity-to-Asset

Anti-Microbialvior BioteQ Co (ROCO:6864) Equity-to-Asset : 0.95 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Anti-Microbialvior BioteQ Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Anti-Microbialvior BioteQ Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$121.05 Mil. Anti-Microbialvior BioteQ Co's Total Assets for the quarter that ended in Dec. 2023 was NT$128.05 Mil. Therefore, Anti-Microbialvior BioteQ Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.95.

The historical rank and industry rank for Anti-Microbialvior BioteQ Co's Equity-to-Asset or its related term are showing as below:

ROCO:6864' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.92   Med: 0.95   Max: 1
Current: 0.95

During the past 6 years, the highest Equity to Asset Ratio of Anti-Microbialvior BioteQ Co was 1.00. The lowest was 0.92. And the median was 0.95.

ROCO:6864's Equity-to-Asset is ranked better than
94.8% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs ROCO:6864: 0.95

Anti-Microbialvior BioteQ Co Equity-to-Asset Historical Data

The historical data trend for Anti-Microbialvior BioteQ Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anti-Microbialvior BioteQ Co Equity-to-Asset Chart

Anti-Microbialvior BioteQ Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.93 0.96 0.92 0.95 0.95

Anti-Microbialvior BioteQ Co Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only 0.92 0.92 0.95 0.96 0.95

Competitive Comparison of Anti-Microbialvior BioteQ Co's Equity-to-Asset

For the Biotechnology subindustry, Anti-Microbialvior BioteQ Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anti-Microbialvior BioteQ Co's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anti-Microbialvior BioteQ Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Anti-Microbialvior BioteQ Co's Equity-to-Asset falls into.



Anti-Microbialvior BioteQ Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Anti-Microbialvior BioteQ Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=121.053/128.047
=0.95

Anti-Microbialvior BioteQ Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=121.053/128.047
=0.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anti-Microbialvior BioteQ Co  (ROCO:6864) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Anti-Microbialvior BioteQ Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Anti-Microbialvior BioteQ Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Anti-Microbialvior BioteQ Co (ROCO:6864) Business Description

Traded in Other Exchanges
N/A
Address
Sec.1, Huandong Road, 1 Floor, No. 2, Ln. 31, Xinshi District, Tainan, TWN, 741
Anti-Microbial Savior BioteQ Co Ltd is engaged in drug research and development as well as development and technology patenting of medical fungi.

Anti-Microbialvior BioteQ Co (ROCO:6864) Headlines

No Headlines